News

eHealth: Where IT meets biotech
Enlarge image

Event ReviewEUGermany

eHealth: Where IT meets biotech

16.02.2016 - The application of digital technology in the pharmaceutical and biotechnology sector was the focal point of the 9th Berlin Conference on IP in Life Sciences. According to the 100+ expert attendees, the potential of new technologies was raised through the cooperation of IT and life science specialists.

Thilo Kaltenbach’s analyse is conclusive, “The large pharma companies are rebooting their medical tools and equipment.” The management consultant from Roland Berger was one of the many experts, who highlighted in mid-February at the Berlin Conference on IP in Life Sciences "Digital Health Solutions", the factors that play an important role in E-health applications.

Pharmaceutical and biotech companies are currently sticking to the motto "Service beyond the pill", in particular on new sales and marketing scenarios based on apps and applicators. But in Kaltenbach’s opinion, that’s just the sidelines: "No one knows what ideas will establish themselves in the end. Therefore a large company is highly unlikely to go out on a limb. There is a lot of cooperating and experimenting."

Sanofi presented the issue of E-health from a Big pharma perspective at the annual BIOCOM event. Vice President Francois Nicolas, joint-responsible for diabetes management, stressed at the conference held in the French Embassy in Berlin-Mitte, the diversity of actors in the market and why pharma relies on partnerships with IT giants such as IBM, Qualcomm, Apple or Alphabet. According to Nicolas: "We are currently entering a new era of health management. We need to simplify the patient’s dealings with the disease in everyday life, so that the therapies can be used effectively." Digital solutions, particularly in common diseases such as diabetes, are currently in vogue.

Further sessions at the conference emphasised the significance of digital solutions for the research and development work. Manuel Gea from Bio-Modeling Systems in Paris pointed out, among other things, the unreliability of published data and the need for Smart Data instead of Big Data. The insufficient development of new active substances in many years of clinical trials and patient’s increasing easy access to information was once again the focal point for Roland Brus, the founder of the online platform Mytomorrows. The legal experts from Vossius, among others, informed the attendees why, under certain conditions, software is patentable and which formulations are to be observed.

A pitching session was held at the end of the day. Six invited entrepreneurs from all over Europe presented their business ideas to a jury of investors. In the end, the Bayer Accelerator Berlin-based start-up, Viomedo was the one to convince the jury. The online marketplace aims to bring drug developers and patients together to push-start clinical trials as early and as soon as possible. The crowd favourite, however, was the Spanish firm Mint Labs, which has developed a cloud-based solution for the evaluation of neurobiological MRI scans.

 

© european-biotechnology-news.com/ml+jc

http://www.european-biotechnology-news.com/news/news/2016-01/ehealth-where-it-meets-biotech.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)2.30 EUR27.78%
  • SAREUM HOLDINGS (UK)0.76 GBP26.67%
  • PROTHENA PLC (IE)55.46 USD7.46%

FLOP

  • RENEURON (UK)3.00 GBP-4.46%
  • PHARMING (NL)0.24 EUR-4.00%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%

TOP

  • PROTHENA PLC (IE)55.46 USD53.2%
  • ACTIVE BIOTECH (S)12.40 SEK34.1%
  • NEWRON (CH)18.75 CHF29.3%

FLOP

  • SANTHERA (CH)55.30 CHF-22.1%
  • MOLOGEN (D)2.30 EUR-20.7%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)30.80 SEK1887.1%
  • NICOX (F)10.85 EUR465.1%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%

FLOP

  • BB BIOTECH (D)45.30 EUR-84.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016